Core Insights - LivaNova reported quarterly earnings of $0.81 per share, exceeding the Zacks Consensus Estimate of $0.80 per share, but down from $0.87 per share a year ago, indicating an earnings surprise of 1.25% [1] - The company posted revenues of $321.8 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.48%, compared to $310.1 million in the same quarter last year [2] - LivaNova has surpassed consensus EPS estimates in all four of the last quarters and has topped revenue estimates three times during the same period [2] Earnings Outlook - The future performance of LivaNova's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.78 on revenues of $306.25 million, while for the current fiscal year, the estimate is $3.64 on revenues of $1.32 billion [7] Industry Context - The Medical - Instruments industry, to which LivaNova belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of LivaNova's stock may also be influenced by the overall industry outlook, as empirical research indicates that top-ranked industries outperform lower-ranked ones significantly [8]
LivaNova (LIVN) Tops Q4 Earnings Estimates